Document is current
Any future updates will be listed below
-
Authors
Kumar, Swaminathan
Pelster, Meredith S.
Hasanov, Merve
Guerrieri, Renato A.
Hudgens, Courtney W.
Ledesma, Debora A.
Wang, Fuchenchu
Fischer, Grant M.
Simon, Julie M.
Haydu, Lauren E.
Katlowitz, Kalman V.
Gopal, Y. N. Vashisht
McQuade, Jennifer L.
Kwong, Lawrence N.
Huse, Jason T.
Lazar, Alexander J.
Tetzlaff, Michael T.
Gershenwald, Jeffrey E.
Joon, Aron Y.
Chen, Ken
Li, Ziyi
Ram, Prahlad T.
Ferguson, Sherise D.
Davies, Michael A.
-
Funding
Funding for this research was provided by:
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (FP17016)
Division of Cancer Prevention, National Cancer Institute (P50CA221703-05)
American Cancer Society (134148-MRAT-19-168-01)
Melanoma Research Alliance (687055)
- License Information
-
More Information
Article History
Received: 24 November 2024
Accepted: 3 March 2025
First Online: 15 April 2025
Declarations
:
: MBM samples collected from patients who underwent craniotomy from 1991 to 2015 at MD Anderson Cancer Center was obtained from Central Nervous System (CNS) tissue bank and Melanoma Informatics, Tissue Resource, and Procurement Core (MelCore) facility under a protocol (LAB10-0519, titled “The Molecular Biology of Melanoma Brain Metastases”) approved by the Institutional Review Board.
: Not applicable.
: MAD has been a consultant to Replimmune, Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. MSP receives research funding paid to her institution Sarah Cannon Research Institute, Nashville, TN, United States by Abbvie, Actuate Therapeutics, Affini-T Therapeutics, Agenus, Arcus Biosciences, Astellas, BeiGene, BioNTech, Bristol-Myers Squibb, Codiak Biosciences, Compass Therapeutics, CytomX, Eisai, Elevation Oncology, Elicio, Exelixis, Fate Therapeutics, Fog Pharmaceuticals, Gilead, GlaxoSmithKline, HiberCell, Immune-Onc Therapeutics, Impact Therapeutics, Jazz Pharmaceuticals, Kura Oncology, Leap Therapeutics, Neogene, Novartis, OncXerna Therapeutics, Panbela Therapeutics, Revolution Medicines, Roche, SeaGen, SQZ Biotechnologies, Surface Oncology, Tachyon Therapeutics, Takeda, Translational Genomics, TransThera Sciences, ZielBio, 1200 Pharma. MSP also has a consulting and advisory role, where she receive payments paid to her institution, in Arcus Biosciences, AstraZeneca, CytomX, Daiichi Sankyo, Elevation Oncology, EMD Serono, Ipsen Biopharmaceuticals, Jazz Pharmaceuticals, Pfizer, SeaGen, Stemline Therapeutics, Takeda. Dr. Jason T Huse, an author in this manuscript, is also one of the Editors-in-chief in the Acta Neuropathological communications journal. No other authors disclosed any conflicts of interest to the study presented here.
